Seminars

Dermal Exposure and Absorption of Active Pharmaceutical Ingredients

Affygility Solutions is pleased to present our newest webinar on Dermal Exposure and Absorption of Active Pharmaceutical Ingredients. Upon completion of this webinar, each participant will be able to:

• Describe the basic anatomy and protective functions of human skin
• Discuss the various factors leading to permeation of APIs through the skin
• Discuss dermal exposure control and regulatory requirements
• Describe the various toxicological assays for evaluating APIs for skin absorption potential
• Assessment of dermal exposure in the workplace
• Provide examples of APIs with skin absorption risks
• Discuss various case histories
• Describe the basic principles of dermal exposure risk management

A request for American Board of Industrial Hygiene Certification Maintenance (CM) points has been submitted.

Cost for this session is $295 USD.

Next offering

Tuesday, February 10, 2009, 10am MST

Cost

$295

Duration

90 minutes

Level

Beginner What's this?

Register

Presenters

• Dean Calhoun, CIH

  Dean Calhoun is an American Board of Industrial Hygiene Certified Industrial Hygienist (CIH). He has been an environmental health and safety professional for over 22 years, and has significant experience in the biotechnology and pharmaceutical industries.

  Dean has spoken for a number of professional organizations including the Colorado Safety Association, the Bay Area Environmental Safety Group, the National Association for Environmental Management, the National Safety Council, the Occupational Safety and Health Administration, and the American Industrial Hygiene Association.

• Dr. Joe Nieusma

  Dr. Nieusma is Senior Toxicologist with Affygility Solutions. He has been an environmental health and safety professional for over 19 years, and has spoken for a number of professional organizations including the American Industrial Hygiene Association, and is an associate member of the Society of Toxicology.

  Dr. Nieusma's expertise includes establishing occupational exposure limits for active pharmaceutical ingredients, excipient level justifications, residual solvent justifications and potent compound program development.